Home » Artificial Intelligence, Automation, Funding, health tech, Investments, SigTuple Bangalore-based health startup SigTuple has raised $19 million in a Series B funding led by existing investors Accel Partners and IDG Venture, with participation from Endiya Partners, pi Ventures, VH Capital, Axilor Ventures and Flipkart co-founder Binny Bansal. The startup has also raised venture debt of an undisclosed amount from Trifecta Capital. SigTuple will use the money to expand assembly and distribution of AI100 — a smart device that enables digitisation of different biological samples like blood, urine and semen. “The major chunk (of the money) will go into setting up a manufacturing pipeline so that we can put more devices in the market,” said Rohit Kumar Pandey, chief executive at SigTuple . “We have applied for US FDA and CE certification. Once we go through the stage, it will require more clinical trials for different market deployments.” The startup in a Series A funding in 2017. The startup is building products for automated analysis of medical scans and data to provide a diagnosis. Its primary product is Manthana, an AI platform which provides solutions for analysis of peripheral blood smears, urine and semen sample, retinal scans and chest x-rays. The peripheral blood smear tool Shonit has undergone trials and is being used in beta by partners. I cover health, policy issues such as intermediary liability, data governance, internet shutdowns, and more. Hit me up for tips.
Health start-up SigTuple has raised $19m in series B funding led by existing investors Accel Partners and IDG Ventures, along with an undisclosed amount of venture debt from Trifecta Capital. The Indian-based AI company will use the funding to expand production of its Shonit smart device, which digitises biological samples such as blood, urine and semen. The company has applied for the US Food and Drug Administration certification and the European Economic Area certification mark.